By Kelly Cloonan
Beyond Air has secured a patent for its treatment of non-tuberculous mycobacteria lung infections using gaseous nitric oxide.
The medical device and biopharmaceutical company said Thursday the patent will expire in 2038.
Chief Executive Steve Lisi said the patent strengthens the company's intellectual property portfolio and reinforces the potential of its LungFit program.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 24, 2025 17:23 ET (21:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.